Mesothelin

Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020

Friday, May 15, 2020 - 2:38pm

Although CAR T cell therapies have been approved for certain hematologic malignancies, new approaches are needed in solid tumor settings.

Key Points: 
  • Although CAR T cell therapies have been approved for certain hematologic malignancies, new approaches are needed in solid tumor settings.
  • Mesothelin is a tumor-specific antigen that is commonly expressed at high levels on the cell surface in many aggressive solid tumors including mesothelioma.
  • Atara has selected mesothelin as the target for both the ATA2271 autologous and the ATA 3271 allogeneic programs along with novel CAR T-cell technologies to further enhance activity.
  • Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

Friday, May 15, 2020 - 5:01am

These two tumor-targeting binding domains can bind together when there's more target present, a property called avidity, said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor.

Key Points: 
  • These two tumor-targeting binding domains can bind together when there's more target present, a property called avidity, said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor.
  • At AACR, we are presenting data from preclinical models showing strong, selective tumor killing from XmAb 2+1 bispecific antibody programs that target PSMA, mesothelin and ENPP3, the last of which is an underexplored tumor antigen overexpressed on renal cell carcinomas.
  • Title: XmAb30819, an XmAb 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in-vivo preclinical studies
    These posters and audio descriptions will be available to registrants of the AACR Virtual Annual Meeting at 9:00 a.m. EDT on Monday, June 22.
  • Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.

TCR² Therapeutics to Present at the Goldman Sachs Cell Therapy Day

Friday, April 3, 2020 - 12:00pm

CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Alfonso Quints Cardama, M.D., Chief Medical Officer of TCR2 Therapeutics, will present an update on company progress during the panel Emergence of TCRs and Next-Generation Therapies at the Goldman Sachs Cell Therapy Day on April 6, 2020 at 2:00pm ET using a virtual platform.

Key Points: 
  • CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Alfonso Quints Cardama, M.D., Chief Medical Officer of TCR2 Therapeutics, will present an update on company progress during the panel Emergence of TCRs and Next-Generation Therapies at the Goldman Sachs Cell Therapy Day on April 6, 2020 at 2:00pm ET using a virtual platform.
  • TCR2Therapeutics Inc.is a clinical-stage immunotherapy company developing the next generation of novel Tcell therapies for patients suffering from cancer.TCR2sproprietary T cell receptor (TCR) Fusion Construct Tcells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent ofhuman leukocyte antigens (HLA).
  • In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
  • The Companys lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.

TCR2 Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

Monday, April 1, 2019 - 12:00pm

"TCR2 has achieved important scientific, clinical, and operational milestones over the past year," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics.

Key Points: 
  • "TCR2 has achieved important scientific, clinical, and operational milestones over the past year," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics.
  • In February, we successfully completed our initial public offering, a significant step for the Company which further strengthened our financial position."
  • TCR2 engineered TC-210 T cells to target and kill mesothelin-expressing cancers while engaging the entire TCR, independent of human leukocyte antigens (HLA).
  • Expanded the TCR2 pipeline, initiating IND-enabling studies for TC-110 and TC-220 product candidates, and building next-generation enhancements into the TRuC platform.

Stand Up To Cancer-supported Clinical Trials Seeking To Extend CAR T-cell Therapy to Solid Tumors, Reported at AACR Annual Meeting

Sunday, March 31, 2019 - 4:00pm

"Many challenges remain, but we are confident that this lifesaving therapy can be deployed even more widely and successfully than it already is."

Key Points: 
  • "Many challenges remain, but we are confident that this lifesaving therapy can be deployed even more widely and successfully than it already is."
  • Two clinical trials supported by SU2C illustrate the promise of CAR T-cell therapy in solid tumors and were featured at a press conference today at the Annual Meeting 2019 of the American Association of Cancer Research, which is also SU2C's Scientific Partner.
  • They are:
    "A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T-cells: Safety and efficacy."
  • "MSLN-targeted CAR T-cell therapy combined with anti-PD1 agents shows encouraging clinical outcomes, thus a combination therapy trial is planned to recruit patients in the second quarter of 2019."

TCR2 Therapeutics Presents Preclinical Data on its Lead Solid Tumor and Blood Cancer Programs at the American Association for Cancer Research (AACR) Annual Meeting

Thursday, March 28, 2019 - 11:00am

Title: Preclinical evaluation of TC-210, a mesothelin-specific T cell receptor (TCR) fusion construct (TRuC) T cells for the treatment of solid tumors.

Key Points: 
  • Title: Preclinical evaluation of TC-210, a mesothelin-specific T cell receptor (TCR) fusion construct (TRuC) T cells for the treatment of solid tumors.
  • Results showed mesothelin-dependent T cell activation, expansion, and tumor clearance by TC-210 was faster than that observed with MSLN CAR-T cells.
  • Additionally, unlike MSLN-CAR-T cells, TC-210 showed increased levels of oxidative phosphorylation and mitochondrial respiratory reserve, attributes associated with long-term memory T cells.
  • Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Bayer Data at AACR 2019 Underscores Company's Commitment to Advancing the Future of Cancer Care

Wednesday, March 27, 2019 - 12:30pm

The AhR inhibitor was discovered and is being developed in collaboration with the German Cancer Research Center (DKFZ, Heidelberg, Germany).

Key Points: 
  • The AhR inhibitor was discovered and is being developed in collaboration with the German Cancer Research Center (DKFZ, Heidelberg, Germany).
  • Research presented includes data on BAY 2315497, a TTC targeting the prostate-specific membrane antigen (PSMA), and BAY 2287411, the mesothelin-targeting TTC.
  • Research presented includes data on anetumab ravtansine as monotherapy in non-small cell lung cancer (NSCLC) pre-clinical models.
  • BAYER, the Bayer Cross, Vitrakvi, Aliqopa and Xofigo are registered trademarks of Bayer.

Targovax Announces Publication of New Oncolytic Virus Data in the Journal of Medical Virology and Cancer Gene Therapy

Wednesday, September 12, 2018 - 6:22am

The first paper, entitled "Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model" was published in the Journal of Medical Virology, [Vol 90:16691673, date 24 May 2018].

Key Points: 
  • The first paper, entitled "Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model" was published in the Journal of Medical Virology, [Vol 90:16691673, date 24 May 2018].
  • This paper demonstrates that Targovax's oncolytic virus, ONCOS-102, induces T-cells specific to the tumor associated antigen (TAA) mesothelin in a mesothelioma mouse model.
  • The second paper, entitled "Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401" was published in Cancer Gene Therapy on 30 July 2018.
  • Magnus Jderberg, Chief Medical Officer at Targovax, commented:
    "The data published in these leading peer reviewed journals provides further scientific evidence for the broad potential of our ONCOS oncolytic virus platform.

Targovax Announces Publication of New Oncolytic Virus Data in the Journal of Medical Virology and Cancer Gene Therapy

Wednesday, September 12, 2018 - 6:12am

The first paper, entitled "Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model" was published in the Journal of Medical Virology, [Vol 90:16691673, date 24 May 2018].

Key Points: 
  • The first paper, entitled "Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model" was published in the Journal of Medical Virology, [Vol 90:16691673, date 24 May 2018].
  • This paper demonstrates that Targovax's oncolytic virus, ONCOS-102, induces T-cells specific to the tumor associated antigen (TAA) mesothelin in a mesothelioma mouse model.
  • The second paper, entitled "Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401" was published in Cancer Gene Therapy on 30 July 2018.
  • Magnus Jderberg, Chief Medical Officer at Targovax, commented:
    "The data published in these leading peer reviewed journals provides further scientific evidence for the broad potential of our ONCOS oncolytic virus platform.